摘要
目的探讨食管鳞癌患者中酸性富含半胱氨酸分泌型蛋白(SPARC)表达与术后临床特征及预后的相关性。方法随机选择在郑州大学附属肿瘤医院行手术治疗的初诊食管鳞癌患者89例,收集肿瘤标本和癌旁正常组织,应用免疫组织化学法检测SPARC蛋白的表达,统计分析其与患者临床特征和预后的相关性。结果食管鳞癌组织SPARC蛋白阳性表达率显著高于癌旁组织(65.17%vs.8.00%,P=0.000),SPARC蛋白优势定位于肿瘤细胞间质中。SPARC蛋白表达与术后淋巴结转移呈负相关(OR=0.369,P=0.038),与病理大体形态、肿瘤分化程度和其他临床特征无关。食管鳞癌患者术后生存与SPARC蛋白表达无关(HR=0.80,P=0.691),而与肿瘤部位(HR=0.34,P=0.037)、分化程度(HR=4.12,P=0.000)和分期(HR=6.36,P=0.017)有关。结论 SPARC蛋白在食管鳞癌间质中高表达,与淋巴结转移负相关,与食管鳞癌术后生存无关。
Objective To explore the correlation between the expression of secreted protein acidic and rich in cysteine(SPARC) and the prognosis of postoperative patients with esophageal squamous cell carcinoma(ESCC).Methods Eighty-nine postoperative patients with ESCC treated in the Affiliated Cancer Hospital of Zhengzhou University were included in the investigation.The expression of SPARC protein was detected in ESCC specimen and normal esophageal mucosa by immunohistochemistry method.The relationship of SPARC protein expression with patients' clinical characteristics and prognosis was analyzed statistically.Results The expression of SPARC protein was signifi cantly up-regulated in ESCC sample compared with normal esophageal mucosa(65.17% vs.8.00%,P=0.000),and predominately located in tumor stroma.SPARC protein expression was negatively correlated with lymph node metastasis(OR=0.369,P=0.038) while it was not related with gross morphology,differentiation grade or other clinical characteristics.Postoperative patient survival was not associated with SPARC protein expression(HR=0.80,P=0.691),but it was related with tumor site(HR=0.34,P=0.037),differentiation grade(HR=4.12,P=0.000) and stage(HR=6.36,P=0.017).Conclusion SPARC protein dominantly expresses in the stroma of ESCC.It is negatively related with lymph node metastasis and does not display the association with the prognosis of postoperative ESCC patients.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2016年第1期35-38,共4页
Cancer Research on Prevention and Treatment
关键词
酸性富含半胱氨酸分泌型蛋白
食管鳞癌
预后
Secreted protein acidic and rich in cysteine(SPARC)
Esophageal squamous cell carcinoma(ESCC)
Prognosis